Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2019-02-04 Regulatory Filings
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-02-04 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-31 English
13G AMENDED ANNUAL FILING - AGLE
Major Shareholding Notification
2019-01-31 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering. It includes detailed information about the types of securities to be offered, the maximum aggregate offering price, and the terms of the offering. The document is a registration statement under the Securities Act of 1933, not a financial report or earnings release. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or a brief notice, confirming it is the actual filing of the registration statement.
2018-12-21 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 17, 2018. It reports the termination of a material definitive agreement related to a capital raising arrangement (an 'at-the-market offering' sales agreement) and the entry into a new sales agreement. The content focuses on capital/financing activities, specifically the termination of one capital raising agreement and the initiation of another. The document length is 3219 characters, which is relatively short but contains substantive information about financing activities rather than just announcing a report or providing a certification. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-12-21 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 11, 2018. It reports a Regulation FD Disclosure regarding a clinical update conference call presentation about a Phase 3 trial design. The document includes a presentation as Exhibit 99.1 and states that the presentation is available on the company's website. The text explicitly states that the information is furnished and not filed, and it is a disclosure of a presentation during a conference call. The document length is 3646 characters, which is relatively short and consistent with an 8-K filing announcing a presentation rather than the presentation itself or a full report. The content is about a presentation given during a conference call, which aligns with the definition of an Investor Presentation (IP). Therefore, the document is best classified as an Investor Presentation (IP).
2018-12-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.